Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Larimar Therapeutics (Nasdaq: LRMR) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12–15, 2026. Management presentation is scheduled for Wednesday, January 14, 2026, 9:00–9:40 AM PST, and the team will participate in 1x1 investor meetings during the conference.
A live webcast will be available at the conference portal and a replay will be posted on Larimar’s Events and Presentations page for 30 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, LRMR declined 0.87%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Several biotech peers such as ASMB (-3.04%), BNTC (-12.98%), DMAC (-6.28%), DRUG (-6%), and RCKT (-5.22%) were also down, suggesting broader biotech weakness, though LRMR’s move appears more stock-specific given the neutral conference headline.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 05 | Q3 2025 earnings | Positive | -15.3% | Strong FA data and cash runway update paired with Q3 financials. |
| Sep 29 | Clinical data update | Negative | -33.7% | Positive FA efficacy signals offset by seven anaphylaxis events and protocol changes. |
| Sep 28 | Conference call setup | Neutral | -33.7% | Scheduled call to discuss nomlabofusp development and open‑label study data. |
| Aug 14 | Q2 2025 earnings | Positive | +14.5% | Robust cash position, BLA timing, and program progress including FDA feedback. |
| Jul 31 | Equity offering | Negative | -0.6% | Underwritten stock offering to fund nomlabofusp and corporate purposes. |
LRMR has often sold off on otherwise positive clinical and financial updates, with notable declines after Q3 2025 results and positive nomlabofusp data, while a Q2 2025 update with financing support saw a strong gain.
Over the last six months, Larimar reported key milestones around nomlabofusp and its financial position. On Aug 14, 2025 it posted Q2 2025 results with $203.6M pro forma cash and a planned BLA in Q2 2026, followed by a $69.0M offering closing on Jul 31, 2025. Positive long‑term FA data and conference communications around Sep 28–29, 2025 were followed by sharp declines, and Q3 2025 results on Nov 5, 2025 also saw weakness despite a $175.4M cash balance. Today’s J.P. Morgan conference appearance continues this pattern of active investor outreach.
Market Pulse Summary
This announcement highlights Larimar’s participation at a major healthcare investor conference, with a scheduled presentation on January 14, 2026 and a replay available for 30 days. In recent months the company has reported substantial cash balances, ongoing development of nomlabofusp for Friedreich’s ataxia, and plans for a potential BLA in Q2 2026. Investors may watch for any new clinical, regulatory, or financial disclosures that emerge from the presentation or follow‑up meetings.
AI-generated analysis. Not financial advice.
BALA CYNWYD, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12 – 15, 2026.
Details on the presentation can be found below.
Date: Wednesday, January 14, 2026
Time: 9:00 – 9:40 AM PST
Following the conclusion of the presentation, a replay will be available for 30 days on the “Events and Presentations” page of Larimar’s website.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
When will Larimar Therapeutics (LRMR) present at the J.P. Morgan Healthcare Conference?
How can investors watch the Larimar Therapeutics (LRMR) presentation live?
Will there be a replay of the Larimar Therapeutics (LRMR) presentation and for how long?
Is Larimar Therapeutics (LRMR) holding investor meetings at the J.P. Morgan conference?
Where and when is the 44th Annual J.P. Morgan Healthcare Conference taking place?
